Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Molecular Signaling

Background:

• Therapeutic resistance in metastatic cancer is a major challenge, driven by cancer stem cells (CSCs).
• CSCs are quiescent and difficult to eradicate, contributing to treatment failure.
• The Wnt signaling pathway is crucial for CSC regulation and represents a therapeutic target.

Purpose of the Study:

• To investigate the mechanism by which RRx-001, an anticancer agent, overcomes therapeutic resistance.
• To determine if RRx-001 targets cancer stem cells (CSCs) and affects Wnt pathway signaling.
• To evaluate RRx-001's effect on CD133+/CD44+ CSCs in colon cancer cell lines.

Main Methods:

• Treatment of HT-29, Caco-2, and HCT116 colon cancer cell lines with RRx-001.
• Analysis of RRx-001's effect on CD133 and CD44 expression in CSCs.
• Assessment of Wnt pathway signaling inhibition and c-Myc downregulation.

Main Results:

• RRx-001 effectively targets CD133+/CD44+ cancer stem cells (CSCs) in HT-29, Caco-2, and HCT116 cells.
• RRx-001 treatment led to significant inhibition of Wnt pathway signaling.
• Downregulation of c-Myc was observed following RRx-001 administration.

Conclusions:

• RRx-001 demonstrates a mechanism for overcoming therapeutic resistance by targeting CSCs.
• Inhibition of Wnt signaling and c-Myc downregulation are key effects of RRx-001 in CSCs.
• These findings support RRx-001's potential as a radio- and chemosensitizing agent in cancer therapy.